

**VALNEVA SE**

World Trade Center Lyon  
Tour Oxygène  
10-12 boulevard Marius Vivier Merle  
69007 Lyon, France

## Valneva Announces Publication of its Registration Document

**Lyon (France), March 22, 2018** – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, announces today the publication of its 2017 Registration Document (“Document de Référence”), filed with the French Financial Market Authority (“Autorité des Marchés Financiers”) under the filing number D.18-0159 on March 21, 2018.

Valneva’s 2017 Registration Document includes the Company’s 2017 Annual Financial Report, and notably:

- + the Separate Financial Statements;
- + the Consolidated Financial Statements (including the amount of fees paid to the Statutory Auditors);
- + the Report by the Supervisory Board on the Corporate Governance.

In addition, the 2017 Registration Document contains the Company’s 2017 Management Report, including a description of Valneva’s share buy-back program, the Group’s Corporate Social Responsibility Report and the information related to the internal control procedures and risk management.

It is available on the Company’s corporate website ([www.valneva.com/en/investors-media/registration-document](http://www.valneva.com/en/investors-media/registration-document)) and on the AMF website ([www.amf-france.org](http://www.amf-france.org)). A hard copy of the document may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

### About Valneva SE

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO<sup>®</sup>/JESPECT<sup>®</sup> indicated for the prevention of Japanese encephalitis and DUKORAL<sup>®</sup> indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including unique vaccines against Lyme disease and Chikungunya. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 450 employees. More information is available at [www.valneva.com](http://www.valneva.com).

### Contacts:

Laetitia Bachelot-Fontaine  
Global Head of Investor Relations  
& Corporate Communications  
M +33 (0)6 4516 7099  
[investors@valneva.com](mailto:investors@valneva.com)

Teresa Pinzolits  
Corporate Communications Specialist  
T +43 1206 201 116  
[communications@valneva.com](mailto:communications@valneva.com)

